Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination (Q36174480)

12 August 2017

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination (English)

1 reference

12 August 2017

0 references

1 reference

7

Uwe-Karsten Hanisch

1 reference

12 August 2017

Wolfgang Brück

1

1 reference

12 August 2017

Ramona Pförtner

2

1 reference

12 August 2017

Trinh Pham

3

1 reference

12 August 2017

Jingya Zhang

4

1 reference

12 August 2017

Liat Hayardeny

5

1 reference

12 August 2017

Victor Piryatinsky

6

1 reference

12 August 2017

Tommy Regen

8

1 reference

12 August 2017

Denise van Rossum

9

1 reference

12 August 2017

Lars Brakelmann

10

1 reference

12 August 2017

Karin Hagemeier

11

1 reference

12 August 2017

Tanja Kuhlmann

12

1 reference

12 August 2017

Christine Stadelmann

13

1 reference

12 August 2017

Gareth R John

14

1 reference

12 August 2017

Nadine Kramann

15

1 reference

12 August 2017

Christiane Wegner

16

1 reference

12 August 2017

6 July 2012

1 reference

12 August 2017

Acta Neuropathologica

1 reference

12 August 2017

124

1 reference

12 August 2017

3

1 reference

12 August 2017

411-424

1 reference

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Oral laquinimod therapy in relapsing multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Statin therapy inhibits remyelination in the central nervous system.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Axonal transection in the lesions of multiple sclerosis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Nuclear factor kappa B, a mediator of lipopolysaccharide effects

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Axonal damage in acute multiple sclerosis lesions.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Neurite outgrowth is impaired on HSP70-positive astrocytes through a mechanism that requires NF-kappaB activation

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Triflusal posttreatment inhibits glial nuclear factor-kappaB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Demyelination: the role of reactive oxygen and nitrogen species

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3422618

Protective Role of Reactive Astrocytes in Brain Ischemia

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00401-012-1009-1

Detection of ventricular enlargement in patients at the earliest clinical stage of MS

21 January 2018

1 reference

12 December 2020

Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma

1 reference

12 December 2020

Myelin-induced experimental allergic encephalomyelitis in Lewis rats: tumor necrosis factor alpha levels in serum and cerebrospinal fluid immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord

1 reference

12 December 2020

Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist

1 reference

12 December 2020

Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis

1 reference

12 December 2020

Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling

1 reference

12 December 2020

Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro

1 reference

12 December 2020

Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination

1 reference

12 December 2020

Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype

1 reference

12 December 2020

Insight into the mechanism of laquinimod action

1 reference

12 December 2020

10.1007/S00401-012-1009-1

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22766690

1 reference